It appears to be superior to standard antibody-based quality-control tests currently used for that purpose, but such scientific advances will need to undergo extensive validation studies before they can be considered a reliable predictor of effects in vivo and eliminate the need for clinical data.
FORBES: Do You Think 'Biosimilars' Will Reduce Healthcare Expenditures? Think again.